DEPDC1 and KIF4A Synergistically Inhibit the Malignant Biological Behavior of Osteosarcoma Cells Through Hippo Signaling Pathway

Overview

Journal J Orthop Surg Res

Publisher Biomed Central

Specialty Orthopedics

Date 2023 Feb 28

PMID 36849972

Authors

Mingming Yang

Hang Zhang

Shichang Gao

Wei Huang

Affiliations

Soon will be listed here.

Abstract

The treatment of osteosarcoma (OS) is still mainly surgery combined with systematic chemotherapy, and gene therapy is expected to improve the survival rate of patients. This study aimed to explore the effect of DEP domain 1 protein (DEPDC1) and kinesin super-family protein 4A (KIF4A) in OS and understand its mechanism. Th expression of DEPDC1 and KIF4A in OS cells was detected by RT-PCR and western blot. The viability, proliferation, invasion and migration of OS cells and tube formation of human umbilical vein endothelial cells (HUVECs) after indicated treatment were in turn detected by CCK-8 assay, EdU staining, wound healing assay, transwell assay and tube formation assay. The interaction between DEPDC1 and KIF4A was predicted by STRING and confirmed by co-immunoprecipitation. The expression of epithelial-mesenchymal transition (EMT)-related proteins, tube formation-related proteins and Hippo signaling pathway proteins was detected by western blot. As a result, the expression of DEPDC1 and KIF4A was all increased in U2OS cells. Down-regulation of DEPDC1 suppressed the viability, proliferation, invasion and migration of U2OS cells and tube formation of HUVECs, accompanied by the increased expression of E-cadherin and decreased expression of N-cadherin, Vimentin and VEGF. DEPDC1 was confirmed to be interacted with KIF4A. Upregulation of KIF4A partially reversed the effect of DEPDC1 interference on the above biological behaviors of U2OS cells. Down-regulation of DEPDC1 promoted the expression of p-LATS1 and p-YAP in Hippo signaling pathway, which was reversed by upregulation of KIF4A. In conclusion, down-regulation of DEPDC1 inhibited the malignant biological behavior of OS cells through the activation of Hippo signaling pathway, which could be reversed by upregulation of KIF4A.

Citing Articles

Roles of DEPDC1 in various types of cancer (Review).

Liu D, Li H, Ouyang J Oncol Lett. 2024; 28(5):518.

PMID: 39296974 PMC: 11409430. DOI: 10.3892/ol.2024.14651.

DEPDC1 affects autophagy-dependent glycolysis levels in human osteosarcoma cells by modulating RAS/ERK signaling through TTK.

Yu D, Chen L, Li Y, Liu B, Xiao W Anticancer Drugs. 2024; 35(10):893-901.

PMID: 39016842 PMC: 11658021. DOI: 10.1097/CAD.0000000000001643.

Targeting DEP domain containing 1 in anaplastic thyroid carcinoma: Implications for stemness regulation and malignant phenotype suppression.

Zhu C, Ke S, Li Y, Zhang W, Che Y, Zhang R Heliyon. 2024; 10(5):e27150.

PMID: 38449652 PMC: 10915564. DOI: 10.1016/j.heliyon.2024.e27150.

Single cell RNA sequencing reveals endothelial cell killing and resolution pathways in experimental malaria-associated acute respiratory distress syndrome.

Pollenus E, Possemiers H, Knoops S, Prenen F, Vandermosten L, Thienpont C PLoS Pathog. 2024; 20(1):e1011929.

PMID: 38236930 PMC: 10826972. DOI: 10.1371/journal.ppat.1011929.

References

Cepeda M, Sosa A, Mora G . [Telangiectatic osteosarcoma in an infant]. Bol Med Hosp Infant Mex. 2018; 74(1):60-64. DOI: 10.1016/j.bmhimx.2016.11.007. View

Mi Y, Zhang C, Bu Y, Zhang Y, He L, Li H . DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB Rep. 2015; 48(7):413-8. PMC: 4577292. DOI: 10.5483/bmbrep.2015.48.7.036. View

Geller D, Gorlick R . Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2011; 8(10):705-18. View

Ma Y, Guo J, Li D, Cai X . Identification of potential key genes and functional role of CENPF in osteosarcoma using bioinformatics and experimental analysis. Exp Ther Med. 2021; 23(1):80. PMC: 8652394. DOI: 10.3892/etm.2021.11003. View

Maugeri-Sacca M, De Maria R . The Hippo pathway in normal development and cancer. Pharmacol Ther. 2018; 186:60-72. DOI: 10.1016/j.pharmthera.2017.12.011. View

Xia J, Zeng M, Zhu H, Chen X, Weng Z, Li S . Emerging role of Hippo signalling pathway in bladder cancer. J Cell Mol Med. 2017; 22(1):4-15. PMC: 5742740. DOI: 10.1111/jcmm.13293. View

Deel M, Li J, Crose L, Linardic C . A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol. 2015; 5:190. PMC: 4557106. DOI: 10.3389/fonc.2015.00190. View

Li Y, Li W, Chang G, Li Y . Long noncoding RNA KTN1 antisense RNA 1exerts an oncogenic function in lung adenocarcinoma by regulating DEP domain containing 1 expression via activating epithelial-mesenchymal transition. Anticancer Drugs. 2021; 32(6):614-625. DOI: 10.1097/CAD.0000000000001035. View

Sun X, Chen P, Chen X, Yang W, Chen X, Zhou W . KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma. Thorac Cancer. 2020; 12(4):512-524. PMC: 7882383. DOI: 10.1111/1759-7714.13787. View

10.

Li N, Feng Y, Hu Y, He C, Xie C, Ouyang Y . Helicobacter pylori CagA promotes epithelial mesenchymal transition in gastric carcinogenesis via triggering oncogenic YAP pathway. J Exp Clin Cancer Res. 2018; 37(1):280. PMC: 6251132. DOI: 10.1186/s13046-018-0962-5. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Guo W, Li H, Liu H, Ma X, Yang S, Wang Z . DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway. Oncol Rep. 2019; 42(3):1075-1089. PMC: 6667871. DOI: 10.3892/or.2019.7221. View

13.

Dong L, Lin F, Wu W, Liu Y, Huang W . Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway. Int J Med Sci. 2018; 15(6):645-652. PMC: 5930467. DOI: 10.7150/ijms.23460. View

14.

Juan W, Hong W . Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. Genes (Basel). 2016; 7(9). PMC: 5042386. DOI: 10.3390/genes7090055. View

15.

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

16.

Ponting C, Bork P . Pleckstrin's repeat performance: a novel domain in G-protein signaling?. Trends Biochem Sci. 1996; 21(7):245-6. View

17.

Pan J, Lei X, Mao X . Identification of KIF4A as a pan-cancer diagnostic and prognostic biomarker via bioinformatics analysis and validation in osteosarcoma cell lines. PeerJ. 2021; 9:e11455. PMC: 8142929. DOI: 10.7717/peerj.11455. View

18.

Zhu D, Xu X, Zhang M, Wang T . Enhanced expression of KIF4A in osteosarcoma predicts a poor prognosis and facilitates tumor growth by activation of the MAPK pathway. Exp Ther Med. 2021; 22(5):1339. PMC: 8495555. DOI: 10.3892/etm.2021.10774. View

19.

Wu Z, Wang C, Chen Y, Sun Z, Yan W . SRPX2 Promotes Cell Proliferation and Invasion in Osteosarcoma Through Regulating Hippo Signaling Pathway. Onco Targets Ther. 2020; 13:1737-1749. PMC: 7049857. DOI: 10.2147/OTT.S225602. View

20.

Kharrat A, Millevoi S, Baraldi E, Ponting C, Bork P, Pastore A . Conformational stability studies of the pleckstrin DEP domain: definition of the domain boundaries. Biochim Biophys Acta. 1998; 1385(1):157-64. DOI: 10.1016/s0167-4838(98)00041-7. View